Case Study 2

American Diabetes Association . Standards of medical care in diabetes—2006. Diabetes Care.2006;29: S4-S42.

American Association of Clinical Endocrinologists . State of Diabetes in America. Available at: http://www.aace.com/public/awareness/stateofdiabetes/DiabetesAmericaReport.pdf. Accessed August 22, 2006.

Kendall DM , Riddle MC , Rosenstock J , et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care.2005;28: 1083-1091.

Siminerio L. Challenges and strategies for moving patients to injectable medications. Diabetes Educ.2006;32(suppl 2): 82S-90S.

Luna B , Feinglos MN. Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician.2001;63: 1747-1756, 1759-1780.

Byetta [package insert]. San Diego, Calif: Amylin Pharmaceuticals; 2006.

Buse JB , Henry RR , Han J , Kim DD , Fineman MS , Baron AD , for the Exenatide-113 Clinical Study Group . Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care.2004;27: 2628-2635.

DeFronzo RA , Ratner RE , Han J , Kim DD , Fineman MS , Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care.2005;28;1092-1100.

Bhatia R , Viswanathan P , Chaudhuri A , Mohanty P , Bhatia V , Dandona P. Exenatide causes weight loss and a reduction in the insulin dose along with an improvement in HbA1c in obese type 2 diabetics on insulin. Poster presented at: 66th Scientific Sessions of the American Diabetes Association; June 9-13, 2006; Washington, DC. Abstract 442-P.

Hood RC. Exenatide (EXE) use in T2DM with A1C ≤7%. Poster presented at: 66th Scientific Sessions of the American Diabetes Association; June 9-13, 2006; Washington, DC. Abstract 488-P.

Zinman B , Hoogwerf B , Garcia SD , et al. Safety and efficacy of exentide in patients with type 2 diabetes mellitus using thiazolidinediones with or without metformin. Poster presented at: 66th Scientific Sessions of the American Diabetes Association; June 9- 13, 2006; Washington, DC. Abstract 117-OR.

Henry RR , Ratner RE , Stonehouse AH , et al. Exenatide maintained glycemic control with associated weight reduction over 2 years in patients with type 2 diabetes. Poster presented at: 66th Scientific Sessions of the American Diabetes Association; June 9-13, 2006; Washington, DC. Abstract 485-P.

Kim D , Macconell L , Zhuang D , et al. Safety and effects of a once-weekly, long-acting release formulation of exenatide over 15 weeks in patients with type 2 diabetes. Poster presented at: 66th Scientific Sessions of the American Diabetes Association; June 9-13, 2006; Washington, DC. Abstract 487-P.

Linnebjerg H , Park S , Kothare P , et al. Effects of exenatide on gastric emptying and postprandial glucose in type 2 diabetes. Poster presented at: 66th Scientific Sessions of the American Diabetes Association; June 9-13, 2006; Washington, DC. Abstract 116-OR.

Wajcberg E , Triplitt C , Sriwijitkamol A , DeFronzo RA , Cersosimo E. Contribution of glucagon suppression to improved postprandial hyperglycemia induced by exenatide in patients with T2DM. Poster presented at: 66th Scientific Sessions of the American Diabetes Association; June 9-13, 2006; Washington, DC. Abstract 118-OR.